Fieldfisher has advised Synairgen plcon its £87 million fundraising to begin the Phase III trial for a potential inhaled treatment for COVID-19. The fundraising was structured…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
